Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RLYB114
- Development stage
- Preclinical
- Lead developer
- Rallybio
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, PEGylated Peptides → Modified Peptides → Peptides
- Administration
- Intravitreal, Intraocular, Ophthalmic
01
Overview
RLYB114 is a preclinical-stage biological drug developed for the treatment of complement-driven ophthalmic diseases. It is a Complement component C5-targeted Affibody molecule conjugated to polyethylene glycol (PEG) to extend its half-life and is designed for intravitreal administration. The drug aims to inhibit Complement component C5, which plays a central role in ocular inflammation and vision loss associated with diseases such as age-related macular degeneration (AMD), particularly geographic atrophy. Rallybio is developing this therapy in collaboration with EyePoint Pharmaceuticals, utilizing EyePoint’s Durasert technology for sustained intraocular delivery.
- Other names
- SOBI-005SOBI005SOBI 005
02
Targets
C5
Beyond the preview
Go deeper on RLYB114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RLYB114.